Ved Srivastava
Chief Technology Officer Perpetual Medicines
Dr. Srivastava is the Chief Scientific Officer at Perpetual Medicines and has over 30 years of experience in developing peptide therapeutics. He joined Perpetual from Aktis Oncology. He was instrumental in the development of several peptide-based drugs, including the First-in-Class GLP-1, Byetta™, Bydureon™, and the First-in-Class Amylin, Symlin™. He has served as Head of Peptide Chemistry at both GlaxoSmithKline and Amylin Pharmaceuticals. He was also a co-founder at Phoundry Pharmaceuticals and Vice President of Chemistry at both Intarcia and Aktis Oncology. Ved is a former president of the American Peptide Society (APS). Ved has co-authored and published numerous peer-reviewed manuscripts, patents, abstracts, and book chapters. He has published six recent books focused on peptide-based drug discovery and development.
Seminars
This your chance to hear from pioneering executive leaders the peptide space who will discuss their ambitions, strategies and challenges for peptide discovery, targets. indications and development of next generation of peptide drugs.
Key questions to be addressed include:
- What are the future opportunities, promising targets and applications on the horizon for peptide-drugs to achieve the next best in-market approval?
- Where is the next big wave heading after GLP-1 peptides?
- How will peptide-drugs compete against the biologics, antibody and small molecule markets as standards of care?
- Showcasing a traditional drug discovery case study with example of GLP-1 class drugs highlighting the challenges with these approaches
- Demonstrating the application of AI/ML and physics-based tools to design novel peptide binders with drug-like properties, enabling multi-objective optimization toward a potential clinical candidate
- Presenting a case of current β-catenin project using physics-based AI approaches
